Yuyu Pharma Total Liabilities
Yuyu Pharma total liabilities. Based on the latest financial reports, Yuyu Pharma (000220) has total liabilities worth ₩63.32 Billion KRW (≈ $42.91 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Yuyu Pharma asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Yuyu Pharma (2011–2024)
Total liabilities of Yuyu Pharma from 2011 to 2024. This chart illustrates how Yuyu Pharma's total liabilities have evolved over time, based on quarterly financial data. Explore 000220 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Yuyu Pharma Competitors by Total Liabilities
The table below lists competitors of Yuyu Pharma ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Grupo Concesionario del Oeste SA
BA:OEST
|
Argentina | AR$135.88 Billion |
|
Theragen Etex Co.Ltd
KQ:066700
|
Korea | ₩101.29 Billion |
|
NOCTILUCA S.A. ZY -15
F:G0Z
|
Germany | €4.02 Million |
|
VirnetX Holding Corp Common Stock
NASDAQ:VHC
|
USA | $7.91 Million |
|
Mirza International Limited
NSE:MIRZAINT
|
India | Rs1.29 Billion |
|
Electra Battery Materials Corp
V:ELBM
|
Canada | CA$100.05 Million |
|
EPE Capital Partners Ltd
JSE:EPE
|
South Africa | ZAC29.24 Million |
|
Canlan Ice Sports Corp.
TO:ICE
|
Canada | CA$80.61 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Yuyu Pharma's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Yuyu Pharma balance sheet assets.
Liquidity & Leverage Metrics
Yuyu Pharma Total Liabilities Ratios Explained
Yuyu Pharma total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Yuyu Pharma's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Yuyu Pharma (2011–2024)
The table below shows the annual total liabilities of Yuyu Pharma from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩72.62 Billion ≈ $49.22 Million |
-6.72% |
| 2023-12-31 | ₩77.86 Billion ≈ $52.76 Million |
+8.39% |
| 2022-12-31 | ₩71.83 Billion ≈ $48.68 Million |
+11.71% |
| 2021-12-31 | ₩64.30 Billion ≈ $43.58 Million |
+69.82% |
| 2020-12-31 | ₩37.86 Billion ≈ $25.66 Million |
-19.73% |
| 2019-12-31 | ₩47.17 Billion ≈ $31.97 Million |
-2.44% |
| 2018-12-31 | ₩48.35 Billion ≈ $32.77 Million |
+25.08% |
| 2017-12-31 | ₩38.66 Billion ≈ $26.20 Million |
+17.11% |
| 2016-12-31 | ₩33.01 Billion ≈ $22.37 Million |
+7.88% |
| 2015-12-31 | ₩30.60 Billion ≈ $20.73 Million |
+2.29% |
| 2014-12-31 | ₩29.91 Billion ≈ $20.27 Million |
+24.69% |
| 2013-12-31 | ₩23.99 Billion ≈ $16.26 Million |
+25.08% |
| 2012-12-31 | ₩19.18 Billion ≈ $13.00 Million |
-9.87% |
| 2011-12-31 | ₩21.28 Billion ≈ $14.42 Million |
-- |
About Yuyu Pharma
Yuyu Pharma, Inc. develops and markets pharmaceutical products in Korea and United States. The company offers various prescription drugs, non-prescription drugs, quasi-drugs, health functional foods, and other products in the fields of neurology, endocrinology, otolaryngology, etc. The company was formerly known as YuYu Inc. and changed its name to Yuyu Pharma, Inc. in May 2008. Yuyu Pharma, Inc.… Read more